Activity of MMP2 and MMP9 matrix metalloproteinases in patients with myeloproliferative and lymphoproliferative diseases
Abstract
MMP2 and MMP9 matrix metalloproteinases due to their ability to destroy basement membranes collagen and remodeling extracellular matrix (ECM) in the micro-environment of blood progenitor cells in the bone marrow play the important role in hematopoiesis. Displacement of normal hematopoiesis and dissemination of malignant cells in proliferative diseases of blood is also accompanied by catalytic ECM rearrangement. However, it is not known exactly how activity of MMP2 and MMP9 changes in various forms of leukemia and how it is affected by chemotherapeutic drugs. The aim of this study was to determine the influence of anthracycline antibiotics (daunorubicin and adriablastin) on MMP2 and MMP9 activity in blood plasma of patients with acute myeloid leukemia, chronic lymphocytic leukemia and multiple myeloma. It was established that proMMP9 activity was significantly reduced (0,03 ± 0,01 rel. u.) in patients with acute myeloid leukemia before the treatment, however, after chemotherapy, it increased approximately 7 times. Chronic lymphocytic leukemia and multiple myeloma were accompanied by significant increase of MMP9 activity. Application of daunorubicin led to decrease of proMMP9 activity (0,25 ± 0,10 rel. u.) in patients with chronic lymphocytic leukemia. ProMMP9 activity was significantly reduced (16 times) and that of MMP9 increased in case of multiple myeloma. In studying of MMP2 activity it did not significantly change. The conclusion is that the ratio of proMMP9/MMP9 can be used as the additional criterion for monitoring the effectiveness of chemotherapy of proliferative diseases of blood.References
Baklanova, J.V., Ushakova, G.O., 2013. Toksychni efekty ta biohimichnyj kontrol' naslidkiv antracyklinovoi' terapii' [Toxic effects and biochemical control the consequences of anthracycline therapy]. Arhiv Klinichnoi' ta Eksperymental'noi' Medycyny 22(2), 242–248 (in Ukrainian).
Bouchet, S., Bauvois, B., 2014. Neutrophil gelatinaseassociated lipocalin (NGAL), promatrix metalloproteinase-9 (pro-MMP-9) and their complex pro-MMP-9/NGAL in leukaemias. Cancers 6, 796–812.
Fu, J., Chen, X., Zhang, Y., Gu, H., Bai, Y., 2010. CD147 and VEGF co-expression predicts prognosis in patients with acute myeloid leukemia. Jpn. J. Clin. Oncol. 40(11), 1046–1052.
Gajdamaka, N.V., Parovichnikova, E.N., Zavalishina, L.J., Savchenko, V.G., Frank., G.A., 2009. Jekspressija matriksnyh metalloproteinaz i ih ingibitorov v kostnom mozge u bol'nyh ostrymi lejkozami [Expression of matrix metalloproteinases and their inhibitors in the bone marrow of patients with acute leukemia]. Gematologija i Transfuziologija 54(2), 3–10 (in Russian).
Kannaiyan, R., Surana, R., Shin, E.M., Ramachandran, L., Sethi, G., Kumar, A.P., 2012. Targeted inhibition of multiple proin-flammatory signaling pathways for the prevention and treat-ment of multiple myeloma. Chapter 5, 93–128.
Klein, G., Vellenga, E., Fraaije, M.W., Kamps, W.A., De Bont, E.S.J.M., 2004. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit. Rev. Oncol. Hematol. 50, 87–100.
Mittelstadt, M.L., Pate, R.C., 2012. AP-1 mediated transcriptional repression of matrix metalloproteinase-9 by recruitment of histone deacetylase 1 in response to interferon β. PLoS One 7(8), e42152.
Spallarossa, P., Altieri, P., Garibaldi, S., Ghigliotti, G., Barisione, C., Manca, V., Fabbi, P., Ballestrero, A., Brunelli, C., Barsotti, A., 2006. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc. Res. 69, 736–745.
Vadhan-Raj, S., Bueso-Ramos, C.E., Hangoc, G., Christopherson, K., Collard, M., Broxmeyer., H.E., 2005. Expansion of bone marrow progenitors and mobilization of multilineage progenitor cells associated with once-per-cycle administration of the long-acting growth factors pegfilgrastim and darbepoetin alfa with chemotherapy. J. Support. Oncol. 3(2), 22–23.
Van Valckenborgh, E., Asosingh, K., Van Riet, I., Van Camp, B., Vanderkerken K., 2004. Matrix metalloproteinases in multiple myeloma. Cancer Ther. 2, 29–38.
Vygovs'ka, J.I., Karol', J.S., Lukavec'kyj, L.M., Mazurok, A.A., Masljak, Z.V., Matlan, V.L., Novak, V.L., Rudenko, V.P., Cjapka, O.M., 2002. Standarty v gematologii' [Standards in Haematology]. PP Kvart, L'viv (in Ukrainian).
Yu, X.F., Han, Z.C., 2006. Matrix metalloproteinases in bone marrow: Roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol. Histopathol. 21, 519–531.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
